10:19 AM EDT, 07/29/2025 (MT Newswires) -- AbbVie ( ABBV ) said Tuesday it submitted a supplemental new drug application to the US Food and Drug Administration for an oral combination of venclexta and acalabrutinib to treat patients with chronic lymphocytic leukaemia.

The application submission is based on the results from phase 3 trial of the drug regimen that showcased improved progression-free survival compared with chemoimmunotherapy, according to a statement.

Shares were up 1.2% in recent trading.

Price: 190.75, Change: +2.23, Percent Change: +1.18